20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
HELIXBALANCE is part of the HELIXAFE prevention model, and aims at analyzing genomic instability, which refers to a high rate of progressive accumulation of somatic mutations and alteration inside a cell’s genome. It is not a marker of cancer risk; rather, it is indicative of the stage, developed over several years, during which cells have progressively accumulated mutations, in individuals with no cancer symptoms (prodromal stage). The simple presence of genetic alterations, even if frequent, is not a marker of genomic instability, which is a matter of rate; instead, a growth trend in somatic mutation frequency, manifested over a prolonged period of time, is indicative of genomic instability. This analysis and the evaluation of factors promoting or insisting on this phenomenon allow real prevention, through the interception of cancer drivers, rather than the detection of an already (even if at early-stage) developed cancer.
